A Human Neutralizing Antibody Specific to Ang‐2 Inhibits Ocular Angiogenesis
- 18 August 2011
- journal article
- research article
- Published by Wiley in Microcirculation
- Vol. 18 (7) , 598-607
Abstract
Please cite this paper as: Rennel, Regula, Harper, Thomas, Klein and Bates (2011). A Human Neutralizing Antibody Specific to Ang-2 Inhibits Ocular Angiogenesis. Microcirculation 18(7), 598–607. Abstract Objective: Angiogenesis, a critical contributor to ocular as well as neoplastic diseases, is stimulated by endothelial production of angiopoietin-2 (Ang2). Our objective was to determine the requirement of ocular angiogenesis for Ang2 in animal models of disease. Methods: We developed and compared the effect of a novel human Ang2 antibody with a pan-angiopoietin strategy on angiogenesis in ocular angiogenesis in animal models of oxygen-induced retinopathy, and laser photocoagulation and confirmed its efficacy in xenografted human colorectal tumors. Results: Human anti-Ang2 and anti-angiopoietin1(Ang1)/Ang2 antibodies blocked colorectal carcinoma growth in immuno-compromised mice (p < 0.001, n = 6). Injection of 1 μg of Ang2 or Ang2/Ang1 antibody-inhibited angiogenesis in models of retinal (p < 0.001, n = 6), and choroidal neovascularization (p < 0.001, n = 11–13 per group) to levels similar to that with anti-VEGF antibodies. There was no difference between Ang2 specific and Ang1/Ang2 bi-specific antibodies. In vitro, Ang2 antibodies showed no cytotoxicity and did not inhibit endothelial cell migration or proliferation. Conclusion: Thus, human Ang2 antibodies are potentially therapeutic agents for ocular neovascularization in models of retinal and choroidal neovascularization, in the absence of VEGF inhibition.Keywords
This publication has 23 references indexed in Scilit:
- Recombinant Human VEGF165b Inhibits Experimental Choroidal NeovascularizationInvestigative Ophthalmology & Visual Science, 2010
- VEGF-A165b Is Cytoprotective and Antiangiogenic in the RetinaInvestigative Ophthalmology & Visual Science, 2010
- Phase 1 Study of AMG 386, a Selective Angiopoietin 1/2–Neutralizing Peptibody, in Combination with Chemotherapy in Adults with Advanced Solid TumorsClinical Cancer Research, 2010
- Complementary Actions of Inhibitors of Angiopoietin-2 and VEGF on Tumor Angiogenesis and GrowthCancer Research, 2010
- Modes of resistance to anti-angiogenic therapyNature Reviews Cancer, 2008
- Vascular Endothelial Growth Factor-A Is a Survival Factor for Retinal Neurons and a Critical Neuroprotectant during the Adaptive Response to Ischemic InjuryThe American Journal of Pathology, 2007
- Ranibizumab for Neovascular Age-Related Macular DegenerationNew England Journal of Medicine, 2006
- Resolution of subretinal haemorrhage and fluid after intravitreal bevacizumab in aggressive peripapillary subretinal neovascularizationActa Ophthalmologica Scandinavica, 2006
- Angiopoietin‐2 enhances retinal vessel sensitivity to vascular endothelial growth factorJournal of Cellular Physiology, 2004
- Tumor Angiogenesis: Therapeutic ImplicationsNew England Journal of Medicine, 1971